<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canadian Medicine &#187; Diabetes</title>
	<atom:link href="http://www.canadianmedicine4all.com/category/diabetes/feed" rel="self" type="application/rss+xml" />
	<link>http://www.canadianmedicine4all.com</link>
	<description></description>
	<lastBuildDate>Thu, 26 Jan 2012 08:54:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
		<item>
		<title>Osteoporosis in men: a study in patients affected by chronic non-advanced liver disease. Patients and methods</title>
		<link>http://www.canadianmedicine4all.com/osteoporosis-in-men-a-study-in-patients-affected-by-chronic-non-advanced-liver-disease-patients-and-methods.html</link>
		<comments>http://www.canadianmedicine4all.com/osteoporosis-in-men-a-study-in-patients-affected-by-chronic-non-advanced-liver-disease-patients-and-methods.html#comments</comments>
		<pubDate>Fri, 16 Dec 2011 10:30:26 +0000</pubDate>
		<dc:creator>David</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[liver disease]]></category>
		<category><![CDATA[men]]></category>
		<category><![CDATA[osteoporosis]]></category>

		<guid isPermaLink="false">http://www.canadianmedicine4all.com/?p=2715</guid>
		<description><![CDATA[In a one year period we studied 98 liver patients consecutively admitted to the III Department of Internal Medicine, Federico II University, Naples, Italy. Among them we selected 25 patients affected by biopsy-proven chronic hepatitis or liver cirrhosis, virus-related, according to the following inclusion criteria: male sex, age &#60; 60 years, body mass index (BMI) [...]]]></description>
		<wfw:commentRss>http://www.canadianmedicine4all.com/osteoporosis-in-men-a-study-in-patients-affected-by-chronic-non-advanced-liver-disease-patients-and-methods.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacoeconomic Analysis of Guidelines for Treating Mild Diabetic Foot Infections: DISCUSSION</title>
		<link>http://www.canadianmedicine4all.com/pharmacoeconomic-analysis-of-guidelines-for-treating-mild-diabetic-foot-infections-discussion.html</link>
		<comments>http://www.canadianmedicine4all.com/pharmacoeconomic-analysis-of-guidelines-for-treating-mild-diabetic-foot-infections-discussion.html#comments</comments>
		<pubDate>Fri, 10 Dec 2010 04:44:16 +0000</pubDate>
		<dc:creator>David</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[cost-effectiveness]]></category>
		<category><![CDATA[diabetic foot infection]]></category>
		<category><![CDATA[oral therapy]]></category>
		<category><![CDATA[pharmacoeconomics]]></category>

		<guid isPermaLink="false">http://www.canadianmedicine4all.com/?p=2074</guid>
		<description><![CDATA[To the authors&#8217; knowledge, this decision-tree model based on the IDSA guideline is the first to be created for Canada. However, its limitations and assumptions may limit its clinical utility. Overall, the decision model presented here may repre­sent an oversimplification of the complexity of treatment of diabetic foot infections, and a model based on guidelines [...]]]></description>
		<wfw:commentRss>http://www.canadianmedicine4all.com/pharmacoeconomic-analysis-of-guidelines-for-treating-mild-diabetic-foot-infections-discussion.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacoeconomic Analysis of Guidelines for Treating Mild Diabetic Foot Infections: RESULTS</title>
		<link>http://www.canadianmedicine4all.com/pharmacoeconomic-analysis-of-guidelines-for-treating-mild-diabetic-foot-infections-results.html</link>
		<comments>http://www.canadianmedicine4all.com/pharmacoeconomic-analysis-of-guidelines-for-treating-mild-diabetic-foot-infections-results.html#comments</comments>
		<pubDate>Fri, 10 Dec 2010 02:38:00 +0000</pubDate>
		<dc:creator>David</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[cost-effectiveness]]></category>
		<category><![CDATA[diabetic foot infection]]></category>
		<category><![CDATA[oral therapy]]></category>
		<category><![CDATA[pharmacoeconomics]]></category>

		<guid isPermaLink="false">http://www.canadianmedicine4all.com/?p=2071</guid>
		<description><![CDATA[Data on probability of clinical success were obtained from RCTs, but the quality of these studies was weak, and the total number of patients in the studies used to construct the model was very small (Table 2). Also, some studies had patients with diabetic foot infections only as a subgroup, and the results may not [...]]]></description>
		<wfw:commentRss>http://www.canadianmedicine4all.com/pharmacoeconomic-analysis-of-guidelines-for-treating-mild-diabetic-foot-infections-results.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacoeconomic Analysis of Guidelines for Treating Mild Diabetic Foot Infections: METHODS part 2</title>
		<link>http://www.canadianmedicine4all.com/pharmacoeconomic-analysis-of-guidelines-for-treating-mild-diabetic-foot-infections-methods-part-2.html</link>
		<comments>http://www.canadianmedicine4all.com/pharmacoeconomic-analysis-of-guidelines-for-treating-mild-diabetic-foot-infections-methods-part-2.html#comments</comments>
		<pubDate>Wed, 08 Dec 2010 18:35:46 +0000</pubDate>
		<dc:creator>David</dc:creator>
				<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[cost-effectiveness]]></category>
		<category><![CDATA[diabetic foot infection]]></category>
		<category><![CDATA[oral therapy]]></category>
		<category><![CDATA[pharmacoeconomics]]></category>

		<guid isPermaLink="false">http://www.canadianmedicine4all.com/?p=2070</guid>
		<description><![CDATA[Data Analysis The analysis was conducted on an intention-to-treat basis: all costs and outcomes were ascribed to the initial drug used, regardless of downstream events. The economic outcome was the expected cost per patient treated for each regimen (i.e., once started on the antibiotic). Clinical outcomes calculated were the expected rates of success (i.e., the [...]]]></description>
		<wfw:commentRss>http://www.canadianmedicine4all.com/pharmacoeconomic-analysis-of-guidelines-for-treating-mild-diabetic-foot-infections-methods-part-2.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

